ABL Bio to Introduce ABL209 at 'World ADC Korea'

Bispecific Antibody ADC Candidate
Phase 1 Clinical Trial Ongoing by NEOK Bio in the United States

ABL Bio announced on June 8 that it will participate in the 5th World ADC Korea 2026, which will be held in Magok, Seoul from June 9 to 11, to introduce its bispecific antibody-drug conjugate (ADC) candidate, ABL209 (NEOK002).

ABL209 is a bispecific ADC developed by ABL Bio that simultaneously targets the Epidermal Growth Factor Receptor (EGFR) and Mucin 1 (MUC1). It incorporates a payload (drug) from the topoisomerase I inhibitor class into the bispecific antibody. Currently, NEOK Bio, a U.S.-based biotech company established by ABL Bio, is conducting a Phase 1 clinical trial of ABL209 in the United States.

ABL Bio will give a presentation on the theme "A bispecific antibody ADC targeting EGFR and MUC1 designed for superior anti-tumor activity and an improved therapeutic window," introducing the process of selecting and validating the target combination for ABL209 and highlighting its competitive edge compared to existing EGFR and MUC1-targeted therapies. The company will share results on anti-tumor activity and toxicity assessments confirmed in preclinical research, and will present the potential for improving the limited therapeutic window (safety) that has been cited as a limitation of conventional single-antibody ADCs.

ABL Bio CEO Sanghoon Lee stated, "ABL Bio is focusing its capabilities on developing next-generation ADCs, including dual payload ADCs, while expanding our ADC pipeline. Through continued research and development, we aim to position ourselves as a leading company in the next-generation ADC market."

This content was produced with the assistance of AI translation services.